CD82 and Familial prostate cancer: Lee et al. [10], for example, found that in prostate cancer cells, CD82 was able to interact with the α3β1/α5β1 integrins to suppress FAK/Src and integrin-linked kinase (ILK) signaling and thereby disrupted the EMT process.